Toxicity and carcinogenicity of riddelliine in rats and mice

Toxicology Letters

Volumn 144, Issue 3, 2003, Pages 295-311

  Chan, Po C ^a   Haseman, Joseph K ^a   Prejean, J D ^b   Nyska, Abraham ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

Arteritis; Carcinogenicity; Hemangiosarcoma; Mice; Rats; Riddelliine

Indexed keywords

CARCINOGEN; RIDDELLINE; UNCLASSIFIED DRUG;

ANGIOSARCOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INJURY; ARTICLE; BIOASSAY; BLEEDING; CANCER MORTALITY; CARCINOGENICITY; CHEMICAL CARCINOGENESIS; CONTROLLED STUDY; CYTOMEGALY; DOSE RESPONSE; EOSINOPHILIA; FEMALE; GASTROINTESTINAL TOXICITY; GLOMERULOSCLEROSIS; KIDNEY DISEASE; KIDNEY INJURY; KIDNEY TUBULE DISORDER; LEUKEMIA CELL; LIVER ADENOMA; LIVER HYPERPLASIA; LIVER INJURY; LIVER NECROSIS; LIVER TOXICITY; LUNG INJURY; MALE; MESENTERY DISEASE; MONONUCLEAR CELL; MOUSE; MOUSE STRAIN; NEPHROTOXICITY; NONHUMAN; OVARY DISEASE; PIGMENT DISORDER; PRIORITY JOURNAL; RAT; RAT STRAIN; SEX RATIO; SPLEEN DISEASE; STATISTICAL SIGNIFICANCE; TOXICOKINETICS; UTERUS DISEASE; VASODILATATION;

EID: 0041632143     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-4274(03)00240-6     Document Type: Article

References (52)

1. Bailer A.J., Portier C.J. Effects of treatment-induced mortality and tumor-induced mortality on tests for carcinogenicity in small samples. Biometrics. 44:1988;417-431.
2. Betz J.M., Eppley R.M., Taylor W.C., Andrzejewski D. Determination of pyrrolizidine alkaloids in commercial comfrey products (Symphytum sp.). J. Pharm. Sci. 83:1994;649-653.
3. Chan P.C., Mahler J., Bucher J.R., Travlos G.S., Reid J.B. Toxicity and carcinogenicity of riddelliine following 13 weeks of treatment to rats and mice. Toxicon. 32:1994;891-908.
4. Chhabra R.S., Huff J.E., Schwetz B.S., Selkirk J. An overview of prechronic and chronic toxicity/carcinogenicity experimental study designs and criteria used by the National Toxicology Program. Environ. Health Perspect. 86:1990;313-321.
5. Chou, M.W., Yan, J., Nichols, J., Xia, Q., Beland, F.A., Chan, P.C., Fu, P.P., 2003. Correlation of DNA adduct formation and riddelliine-induced liver tumorigenesis in F344 rats and B6C3F1 mice. Cancer Lett. 193, 119-125.
6. Cox D.R. Regression models and life-tables. J. R. Stat. Soc. B. 34:1972;187-220.
7. Eustis S.L., Boorman G.A., Harada T., Popp J.A. Liver. Boorman G.A., Eustis S.L., Elwell M.R., Montgomery C.A. Jr., MacKenzie W.F. Pathology of the Fischer Rat: Reference and Atlas. 1990;71-94 Academic Press, San Diego, CA.
8. Fetsch J.F., Weiss S.W. Observations concerning the pathogenesis of epithelioid hemangioma (angiolymphoid hyperplasia). Mod. Pathol. 4:1991;449-455.
9. Fu P.P., Chou M.W., Xia Q., Yang Y.C., Yan J., Doerge D.R., Chan P.C. Environmental genotoxic pyrrolizidine alkaloids and pyrrolizidine alkaloid N-oxides - mechanisms leading to DNA adduct formation and tumorigenicity. Environ. Carcinog. and Ecotoxicol. Rev., Part C. J. Environ. Sci. Health. 19:2001;353-385.
10. Galloway S., Armstrong M., Reuben C., Colman S., Brown B., Cannon C., Bloom A., Namamura F., Ahmed M., Muk S., Rimpo J., Margolin B., Resnick M., Anderson B., Zeiger E. Chromosome aberrations and sister chromatid exchanges in Chinese hamster ovary cells: evaluation of 108 chemicals. Environ. Mol. Mutagen. 10:(Suppl. 10):1987;1-175.
11. Grossblatt N. Guide for the Care and Use of Laboratory Animals. 1996;National Academy Press, Washington, DC.
12. Harris P.N., Chen K.K. Development of hepatic tumors in rats following ingestion of Senecio longilobus. Cancer Res. 30:1970;2881-2886.
13. Haseman S.K., Young E., Eustis S.L., Hailey J.R. Body weight-tumor incidence correlations in long-term rodent carcinogenicity studies. Toxicol. Pathol. 25:1997;256-263.
14. Hincks J.R., Kim H.Y., Segall H.J., Molyneux R.J., Stermitz F.R., Coulombe R.A. Jr. DNA cross-linking in mammalian cells by pyrrolizidine alkaloids: structure-activity relationships. Toxicol. Appl. Pharmacol. 111:1991;90-98.
15. Hirono I., Shimizu M., Fushimi K., Mori H., Kato K. Carcinogenic activity of Petasites japonicus maxim, a kind of coltsfoot. Gann. Monogr. Cancer Res. 64:1973;527-528.
16. Hirono I., Mori H., Yamada K., Hirata Y., Haga M. Carcinogenic activity of petasitenine, a new pyrrolizidine alkaloid isolated from Petasites japonicus Maxim. J. Natl. Cancer Inst. 58:1977;1155-1157.
17. Hirono I., Mori H., Haga M. Carcinogenic activity of Symphytum officinale. J. Natl. Cancer Inst. 61:1978;865-869.
18. Hirono I., Haga M., Fujii M., Matsuura S., Matsubara N., Nakayama M., Furuya T., Hikichi M., Takanashi H., Uchida E., Hosaka S., Ueno I. Induction of hepatic tumors in rats by senkirkine and symphytine. J. Natl. Cancer Inst. 63:1979;469-472.
19. Hirono I., Ueno I., Aiso S., Yamaji T., Haga M. Carcinogenic activity of Farfugium japonicum and Senecio cannabifolius. Cancer Lett. 20:1983;191-198.
20. Hong, H.L., Ton, T.V., Devereux, T.R., Chan, P., Dunnick, J.K., Sills, R.C., in press. Genetic alterations in ras, p53 and b-catenin genes in O-nitrotoluene- and riddelliine-induced hemangiosarcomas of B6C3F1 mice following exposures for 2 years. Toxicol. Appl. Pharmacol.
21. Huxtable R.J. Herbal teas and toxins: novel aspects of pyrrolizidine poisoning in the United States. Perspect. Biol. Med. 24:1980;1-14.
22. IARC, 1976. Pyrrolizidine alkaloids. In: IARC Monograph on the Evaluation of Carcinogenic Risk of Chemicals to Man: Some Naturally Occurring Substances, Vol. 10. International Agency for Research on Cancer, Lyon, France, pp. 265-342.
23. Jones P.L., Rabnovitch M. Tenascin-C is induced with progressive pulmonary vascular disease in rats and is functionally related to increased smooth muscle cell proliferation. Circ. Res. 79:1996;1131-1142.
24. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:1958;457-481.
25. Kuhara K., Takanashi H., Hirono I., Furuya T., Asada Y. Carcinogenic activity of clivorine, a pyrrolizidine alkaloid isolated from Ligularia dentata. Cancer Lett. 10:1980;117-122.
26. Kurozumi T., Tanaka K., Kido M., Shoyama Y. Monocrotaline-induced renal lesions. Exp. Mol. Pathol. 39:1983;377-386.
27. Letendre L., Ludwig J., Perrault J., Smithson W.A., Kovach J.S. Hepatocellular toxicity during the treatment of refractory acute leukemia with indicine N-oxide. Cancer. 54:1984;1256-1259.
28. MacGregor J., Hennika P., Roitman J. Induction of micronuclei in peripheral blood erythrocytes of adult and fetal Swiss mice by pyrrolizidine alkaloids. Environ. Mutagen. 7:(Suppl. 3):1985;68.
29. Mattocks A.R. Chemistry and Toxicology of Pyrrolizidine Alkaloids. 1986;Academic Press, New York.
30. Meyrick B.O., Reid L.Y. Crotalaria-induced pulmonary hypertension: uptake of 3H-thymidine by the cells of the pulmonary circulation and alveolar walls. Am. J. Pathol. 106:1982;84-94.
31. Miranda C.L., Reed R.L., Guengerich F.P., Buhler D.R. Role of cytochrome P450IIIA4 in the metabolism of the pyrrolizidine alkaloid senecionine in human liver. Carcinogenesis. 12:1991;515-519.
32. Mirsalis J. In vivo measurement of unscheduled DNA synthesis and S-phase synthesis as an indicator of hepatocarcinogenesis in rodents. Cell Biol. Toxicol. 3:1987;165-173.
33. Mirsalis J., Tyson K., Beck J., Loh E., Steinmetz K., Contreras C., Auster L., Markin S., Spalding J. Induction of unscheduled DNA synthesis (UDS) in hepatocytes following in vitro and in vivo treatment. Environ. Mutagen. 5:1983;482. (Abstract).
34. Mirsalis J.C., Steinmetz K.L., Blazak W.F., Spalding J.W. Evaluation of the potential of riddelliine to induce unscheduled DNA synthesis, S-phase synthesis, or micronuclei following in vivo treatment with multiple doses. Environ. Mol. Mutagen. 21:1993;265-271.
35. Molyneux R.J., Johnson A.E., Olsen J.D., Baker D.C. Toxicity of pyrrolizidine alkaloids from Riddell groundsel (Senecio riddellii) to cattle. Am. J. Vet. Res. 52:1991;146-151.
36. NTP, 1993. NTP Technical Report on Toxicity Studies of Riddelliine (CAS No. 23246-96-0) Administered by Gavage to F344/N Rats and B6C3F1 Mice. Toxicity Report Series No. 27. NIH Publication No. 94-3350. US Department of Health and Human Services, Public Health Service, National Institutes of Health, Research Triangle Park, NC.
37. NTP, 2001. NTP Technical Report on the Toxicology and Carcinogenesis Studies of Riddelliine (CAS No. 23246-96-0) in F344/N rats and B6C3F1 mice. NTP TR 508. NIH Publication No. 01-4442. US Department of Health and Human Services, Public Health Service, National Institutes of Health, Research Triangle Park, NC.
38. Nyska A., Moomaw C.R., Foley J.F., Malarkey D.E., Cummings C.M., Peddada S., Travlos G., Chan P.C. The hepatic endothelial carcinogen riddelliine induces endothelial apoptosis, mitosis, S phase, and p53 and hepatocytic vascular endothelial growth factor expression after short-term exposure. Toxicol. Appl. Pharmacol. 184:2002;153-164.
39. Rao M.S., Reddy J.K. Malignant neoplasms in rats fed lasiocarpine. Br. J. Cancer. 37:1978;289-293.
40. Roeder E. Medicinal plants in Europe containing pyrrolixidine alkaloids. Pharmazie. 50:1995;83-98.
41. Schoental R., Head M. Progression of liver lesions produced in rats by temporary treatment with pyrrolizidine (senecio) alkaloids and the effects of betaine and high casein diet. Br. J. Cancer. 11:1957;535-544.
42. Shraufnagel D.E. Monocrotaline-induced angiogenesis: differences in the bronchial and pulmonary vasculature. Am. J. Pathol. 137:1990;1083-1090.
43. Svoboda D.J., Reddy J.K. Malignant tumors in rats given lasiocarpine. Cancer Res. 32:1972;908-913.
44. Tarone R.E. Tests for trend in life table analysis. Biometrika. 62:1975;679-682.
45. Taylor D.W., Wilson D.W., Lane M.W., Dunston S.D., Jones A.D., Segall H.J. Comparative cytotoxicity of monocrotaline and its metabolites in cultured pulmonary artery endothelial cells. Toxicol. Appl. Pharmacol. 143:1997;196-204.
46. Verheul H.M., Pinedo H.M. Tumor growth: a putative role for platelets? Oncologist. 3:1998;2.
47. Waltham M., Burnand K.G., Collins M., Smith A. Vascular endothelial growth factor and basic fibroblast growth factor are found in resolving venous thrombi. J. Vasc. Surg. 32:2000;988-996.
48. WHO, 1988. Pyrrolizidine alkaloids. In: International Programme on Chemical Safety, Environmental Health Criteria, Vol. 80, World Health Organization, Geneva, p. 337.
49. Williams D.E., Reed R.L., Kedzierski B., Dannan G.A., Guengerich F.P., Buhler D.R. Bioactivation and detoxication of the pyrrolizidine alkaloid senecionine by cytochrome P-450 enzymes in rat liver. Drug. Metab. Dispos. 17:1989;387-392.
50. Williams L., Chou M.W., Yan J., Young J.F., Chan P.C., Doerge R. Toxicokinetics of riddelliine, a carcinogenic pyrrolizidine alkaloid, and metabolites in rats and mice. Toxicol. Appl. Pharmacol. 182:2002;98-104.
51. Yang Y.-C., Yan J., Doerge D.R., Chan P.C., Fu P.P., Chou M.W. Metabolic activation of the tumorigenic pyrrolizidine alkaloid, riddelliine, leading to DNA adduct formation in vivo. Chem. Res. Toxicol. 14:2001;101-109.
52. Zeiger E., Anderson B., Haworth S., Lawlor T., Mortelmans K. Salmonella mutagenicity tests. IV. Results from the testing of 300 chemicals. Environ. Mol. Mutagen. 11:(Suppl.1):1988;1-158.